Kemble George bought SGMT
August 11, 2026 · Form 4 insider transaction
Kemble George bought 9,751 shares of Sagimet Biosciences Inc. at $6.36 per share, a transaction worth $62.0K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 1 day after the transaction.
Direction
Acquired (buy-side)
Shares
9,751
Price
$6.36
Total value
$62.0K
InsiderKemble George
RoleDirector
SecuritySeries A Common Stock
Transaction codeM: Option exercise
Transaction dateAugust 11, 2026
Filing dateAugust 12, 2026
Shares owned after71,912
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.